After Caronia: First Amendment Concerns in Off-Label Promotion
Stephanie M. Greene
Boston College - Carroll School of Management
January 7, 2014
San Diego Law Review, Vol. 51, No. 3, 2014, Forthcoming
The government has successfully prosecuted pharmaceutical companies for off-label promotion of drugs, maintaining that such promotion impermissibly undermines the FDA’s pre-market approval process and jeopardizes the public health. In several recent cases, however, pharmaceutical companies have alleged that regulations prohibiting such promotion are unconstitutional because off-label promotion is protected under the First Amendment. Two recent Supreme Court cases contain language that gives broad protection to advertising and marketing in the pharmaceutical field. This paper questions the reach of these cases as applied to the practice of off-label promotion through detailing.
Number of Pages in PDF File: 45
Keywords: pharmaceutical, industry, marketing, authority, drug, ads, caputo, sorrell, western states, central hudson, guidance, regulatory, promotion, label, off-label, FDA, FDCA, pre-market, approval, regulations, First Amendment, Supreme Court
JEL Classification: I18, K10, K20, K23, K32, K40, M3, M30, M31, M37, M39Accepted Paper Series
Date posted: January 8, 2014 ; Last revised: January 9, 2014
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo7 in 0.438 seconds